Dec 09, 2020
Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020
Dec 07, 2020
Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
Oct 29, 2020
Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children >=2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)
Oct 21, 2020
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
Oct 21, 2020
Seqirus Announces Late-Breaking Data at IDWeek 2020: New Real-World Evidence Shows Value of Adjuvanted Influenza Vaccine for Adults 65 Years and Older with Underlying Health Conditions
Jul 30, 2020
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Feb 24, 2020
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Dec 09, 2019
New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Aug 31, 2019
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Aug 30, 2019
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Aug 22, 2019
Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
Apr 15, 2019
Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology
Nov 16, 2018
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Nov 16, 2018
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
Oct 23, 2018
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Oct 03, 2018
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
Oct 03, 2018
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
Aug 23, 2018
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
Jul 26, 2018
GISAID announces a major contribution from Seqirus to support open and rapid sharing of influenza virus data
Apr 19, 2018
The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months